Palvella Therapeutics (PVLA) Net Income towards Common Stockholders: 2013-2024
Historic Net Income towards Common Stockholders for Palvella Therapeutics (PVLA) over the last 11 years, with Dec 2024 value amounting to -$3.4 million.
- Palvella Therapeutics' Net Income towards Common Stockholders fell 124.34% to -$3.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$17.4 million, marking a year-over-year decrease of 74.03%. This contributed to the annual value of -$17.4 million for FY2024, which is 197.32% down from last year.
- Latest data reveals that Palvella Therapeutics reported Net Income towards Common Stockholders of -$3.4 million as of Q4 2024, which was up 51.66% from -$7.0 million recorded in Q3 2024.
- Palvella Therapeutics' Net Income towards Common Stockholders' 5-year high stood at $13.8 million during Q4 2023, with a 5-year trough of -$19.0 million in Q3 2021.
- Moreover, its 3-year median value for Net Income towards Common Stockholders was -$7.2 million (2022), whereas its average is -$5.9 million.
- Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first slumped by 1,508.69% in 2020, then soared by 223.93% in 2023.
- Quarterly analysis of 5 years shows Palvella Therapeutics' Net Income towards Common Stockholders stood at -$12.4 million in 2020, then climbed by 11.27% to -$11.0 million in 2021, then dropped by 1.48% to -$11.2 million in 2022, then surged by 223.93% to $13.8 million in 2023, then crashed by 124.34% to -$3.4 million in 2024.
- Its last three reported values are -$3.4 million in Q4 2024, -$7.0 million for Q3 2024, and -$4.4 million during Q2 2024.